Skip to main content
. 2020 Jan 1;16(3):471–482. doi: 10.7150/ijbs.39123

Figure 6.

Figure 6

Diagnostic efficiency of the combination of exosomal lncRNAs and serum Cyfra21-1 for NSCLC. (A-B) ROC curve analysis for the combination of exosomal lncRNAs and Cyfra21-1 in distinguishing NSCLCs overall or stage I NSCLC patients versus healthy controls. (C-D) ROC curve analysis for the combination of exosomal lncRNAs and Cyfra21-1 for ADC patients or SCC patients versus healthy controls.